The National Institute of Child Health and Human Development (NICHD) awarded a $250,300 R21 grant (CFDA 93.865) to Children's Mercy Hospital in Kansas City, Missouri. The grant will fund a Phase I clinical study investigating the use of inhaled ciclesonide, a synthetic glucocorticoid, to prevent bronchopulmonary dysplasia (BPD) in preterm infants born before 30 weeks gestation. The study aims to determine the maximum tolerable dose of inhaled ciclesonide that does not trigger adverse systemic side effects in this population at risk of developing BPD, a leading cause of death and long-term pulmonary issues in premature infants. As part of the grant, the University of Pittsburgh will serve as a sub-awardee, providing research technician support and expertise in mass spectrometry analysis to the project.
Generated 3/4/25, 8:10 AM